Benchmark Reaffirms “Buy” Rating for NeoGenomics (NASDAQ:NEO)
NeoGenomics (NASDAQ:NEO – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Benchmark in a research note issued on Tuesday, Benzinga reports. They currently have a $18.00 target price on the medical research company’s stock. Benchmark’s price target points to a potential upside of 20.32% from the company’s previous close. Several other […]
More Stories
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Announces Monthly Dividend of $0.04 (NYSE:DCF)
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. (NYSE:DCF – Get Free Report) declared a monthly dividend...
First Trust Alternative Absolute Return Strategy ETF (FAAR) to Issue Quarterly Dividend of $0.20 on September 30th
First Trust Alternative Absolute Return Strategy ETF (NASDAQ:FAAR – Get Free Report) declared a quarterly dividend on Wednesday, September 25th,...
First Trust Capital Strength ETF (FTCS) To Go Ex-Dividend on September 26th
First Trust Capital Strength ETF (NASDAQ:FTCS – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports....
AGM Group Holdings Inc. (NASDAQ:AGMH) Short Interest Update
AGM Group Holdings Inc. (NASDAQ:AGMH – Get Free Report) was the recipient of a large growth in short interest in...
Raffles Medical Group Ltd (OTCMKTS:RAFLF) Sees Significant Decrease in Short Interest
Raffles Medical Group Ltd (OTCMKTS:RAFLF – Get Free Report) was the recipient of a significant decrease in short interest in...
Short Interest in Legrand SA (OTCMKTS:LGRDY) Decreases By 90.6%
Legrand SA (OTCMKTS:LGRDY – Get Free Report) was the target of a large decline in short interest in September. As...